Biognosys Announces Strategic Agreement with Siemens Healthineers
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it has established a strategic agreement with Siemens Healthineers, a global medical technology company, through its clinical laboratory in Berkeley, California. The agreement leverages Biognosys’ expertise in unbiased biomarker discovery technologies and solutions with Siemens Healthineers’ biomarker assay development, lab testing, and commercialization capabilities.
Oliver Rinner, PhD, CEO and founder of Biognosys states: “With this agreement we can enable our biopharmaceutical customers to use the power of our proprietary discovery proteomics solution for novel biomarker identification and bring these biomarkers into clinical applications with Siemens Healthineers’ diagnostic assay development expertise.”
Using Biognosys’ proprietary Hyper Reaction Monitoring (HRMTM) mass spectrometry technology, thousands of proteins may be quantified simultaneously from a broad range of clinical sample types. HRM enables an unmatched depth of proteome coverage with reproducible and precise quantification to identify the most promising, actionable biomarkers to support clinical decision making. This discovery proteomics solution can be applied with high throughput in large-scale studies involving thousands of samples.
The strategic agreement enables discovery of novel biomarkers via the HRM technology followed by translation into validated biomarker assays for potential clinical applications. This may include clinical trials usage and In Vitro Diagnostics development programs.
Sebastian Kronmueller, Head of Siemens Healthcare Laboratory in California, commented: “We are excited about this relationship with Biognosys because their expertise and unique biomarker discovery capabilities are very complementary to our end-to-end diagnostic solutions for our biopharmaceutical customers.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions, and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company’s proprietary solutions provide a multi-dimensional view of protein expression, function, and structure in all major biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry for the quantification of thousands of proteins across thousands of samples with industry-leading, precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
About Siemens Healthineers
To learn more about Siemens Healthineers, please visit siemens-healthineers.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005039/en/
Contact information
Media Contact Biognosys
Oliver Rinner, PhD
Chief Executive Officer
Phone +41 (0) 44 738 20 40
oliver.rinner@biognosys.com
Media Contact Siemens Healthineers
Lance Longwell, MBA
Director Of Communications And Public Relations
Phone +1 (610) 883-0788
lance.longwell@siemens-healthineers.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Morningstar's 2026 Outlook Report Delivers Global and Regional Insights for Durable Portfolios17.11.2025 16:00:00 EET | Press release
Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today published its 2026 Outlook, offering an overview of key challenges and opportunities for the year ahead. In a market defined by uncertainty, this year’s report emphasizes the value of preparation over prediction, equipping investors with strategies to focus on fundamentals and help build resilient portfolios that withstand both booms and busts. Drawing on insights from Equity, Manager, and Behavioral research analysts worldwide, this Outlook distills Morningstar’s thinking on how to navigate opportunity and risk across every major asset class in 2026. "Markets are unpredictable, and the geopolitical and tariff uncertainty of 2025 showed just how quickly forecasts can shift. That’s why Morningstar is redefining the Outlook, focusing on durable portfolios rather than short-term predictions,” said Dan Kemp, chief research and investment officer. “No matter what market conditions the year ahead m
Wolters Kluwer Enablon Control of Work Solution Now Available as Private Offer in AWS Marketplace17.11.2025 16:00:00 EET | Press release
Wolters Kluwer today announced that its Enablon Control of Work solution is now available in AWS Marketplace as a private offer. This purchasing model empowers customers to negotiate and receive tailored pricing, terms, and licensing agreements, while streamlining procurement and leveraging existing Amazon Web Services (AWS) billing workflows to accelerate deployment and optimize cloud budgets. Wolters Kluwer’s Enablon Control of Work solution consolidates permit-to-work, isolation management and risk assessments into an integrated system. Trusted by frontline workers and contractors in high-risk environments including oil & gas, pharmaceuticals, data center and manufacturing industries, the software helps streamline operations, minimize unplanned downtime and prevent serious injuries and fatalities. Richard Pulliam, SVP & General Manager of EHS & ESG for Wolters Kluwer, said: “Making Enablon's Control of Work solution available in AWS Marketplace is another step in our mission to help
World First: Autonomous Racing Leaps Forward in Abu Dhabi as A2RL Season 2 Showcases Record Speed, Bold Overtakes and Real-Time AI Decision-Making17.11.2025 15:50:00 EET | Press release
The Abu Dhabi Autonomous Racing League, A2RL, delivered a defining moment for autonomous technology as six fully driverless racecars pushed the limits of AI performance in a world-first Grand Final at Yas Marina Circuit. In a night marked by record speed, bold overtakes, and split-second AI decision-making, Germany’s TUMcemented its dominance by retaining the championship title, followed by TII Racing (UAE) in second place, and PoliMOVE (Italy) in third. With eleven international teams battling for a $2.25 million prize pool and a Human vs AI showdown featuring former F1 star Daniil Kvyat, the event showcased just how dramatically the race - and the technology behind it - has advanced since Season 1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117644875/en/ World First: Autonomous Racing Leaps Forward in Abu Dhabi as A2RL Season 2 Showcases Record Speed, Bold Overtakes and Real-Time AI Decision-Making (Photo: AETOSWire
87% of Institutional Investors Have Declined or Reconsidered Fund Commitments Due to AML/KYC Concerns17.11.2025 15:30:00 EET | Press release
Nearly nine-in-10 (87%) limited partners (LPs) have declined or reconsidered a fund allocation due to anti-money laundering and Know Your Customer (AML/KYC) concerns, underscoring just how significant compliance has become as a gatekeeping item for fundraising. According to a new study by CSC, the leading provider of global business administration and compliance solutions, general partners (GPs) are already feeling the strain. Almost two-thirds (63%) report losing investors or reinvestments due to AML/KYC shortcomings, most commonly from documentation gaps (61%) and onboarding delays (24%). CSC surveyed 200 GPs and 200 LPs across North America, Europe, the U.K., and Asia Pacific to capture views on the evolving compliance landscape.1 The findings are detailed in CSC’s report, “Beyond Compliance: How AML/KYC is Redefining Investor Confidence.” The study found that LPs are setting the pace when it comes to AML/KYC. 88% said they’re more likely to invest in a manager with a formal AML/KYC
Cardano Summit 2025 Concludes In Berlin: Trust Emerges As The Winner with Traditional Financial Firms Feeling Blockchain FOMO17.11.2025 15:23:00 EET | Press release
Last week’s Cardano Summit 2025 at Berlin’s iconic Gasometer heard from 140 speakers, brought together close to 800 attendees from over 70 countries, and attracted over 25,000 online participants, showcasing significant momentum in enterprise blockchain adoption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117496852/en/ Cardano Foundation CEO Frederik Gregaard on the main stage at the Cardano Summit 2025 in Berlin Across two days of strategic discussions, enterprise leaders joined the Cardano community to discuss industry readiness, DeFi expansion, and the convergence of AI with distributed systems. The Cardano Foundation also outlined its 2026 roadmap highlighting decentralized finance (DeFi) liquidity, Web3 integration, and real-world asset (RWA) tokenization as key focus areas. Additionally, Singapore was unveiled as the location for next year’s Summit. Cardano Foundation CEO Frederik Gregaard set an ambitious tone
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom